| abstract |
It is intended to provide a cancer metastasis inhibitor, in particular, a drug which is useful in treating bone metastasis and liver metastasis. Namely, a cancer metastasis inhibitor comprising, as the active ingredient, a substance inhibiting the activities of insulin-like growth factor (IGF)-I and IGF-II. By using this inhibitor, cancer metastasis can be significantly inhibited. |